Poop pills for autism? small study tests gut bacteria fix
NCT ID NCT07371013
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether fecal microbiota transplantation (FMT) capsules can improve gut symptoms like constipation and diarrhea in children with autism, and possibly help their behavior. Twenty children aged 6-12 will be randomly assigned to receive either FMT capsules or a placebo after bowel cleansing. The study lasts about 6 months and tracks stool consistency, pain, and behavioral changes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Fecal microbiota transplantation (FMT) capsules (MBiotix HBI Caps) containing gut bacteria from healthy donors
- What this could lead to
- If it works, this could point toward a new way to ease gut problems and possibly improve behavior in children with autism.
- What could go wrong
- This is a very small, early pilot study with only 20 children. It may not show clear benefits, and the effects could vary widely. Bowel cleansing is required, which can be uncomfortable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Providing informed consent for participation in the study by the child's legal representative - parent or legal guardian. * Diagnosis of autism spectrum disorder according to DSM-5 or ICD-11 criteria. * Ability to swallow an empty test capsule identical in shape and size to the investigational product * Abnormal stool consistency observed by parents for at least 2 months prior to study inclusion. Patients with an average stool consistency greater than 5 on the Bristol Stool Form Scale (BSFS) during the baseline period will be classified as having diarrhea. Patients with an average stool consistency less than 3 on the Bristol Stool Form Scale during the baseline period will be classified as having constipation. Exclusion Criteria: * Presence of a gastrointestinal disease such as celiac disease, food allergy, inflammatory bowel disease, pancreatitis, chronic liver disease, eosinophilic esophagitis, peptic ulcer disease of the stomach or duodenum, Hirschsprung's disease. * Primary or secondary immunodeficiency, including absolute neutrophil count in peripheral blood \<1500 measured within 28 days prior to planned FMT. * History of surgery involving disruption of intestinal continuity within 3 months prior to study inclusion. * Lactose or fructose intolerance. Patients with lactose intolerance who follow an elimination diet and still experience symptoms may be included in the study. * Malnutrition defined as Body Mass Index (BMI) below the 3rd percentile based on Polish growth charts from 2010. * Overweight or obesity defined as BMI above the 85th percentile based on Polish growth charts from 2010. * Active infection requiring antibiotic therapy. * Expected use of antibiotics during participation in the study. * Use of probiotics during participation in the study. * Inability to undergo bowel cleansing therapy (Dicopeg Endo). * Inability to swallow an empty test capsule. * Lack of consent from the child's legal representative - parent or legal guardian - for participation in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autism spectrum disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institute of Mother and Child
Warsaw, Masovian Voivodeship, 01-211, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can wireless monitors make ER vitals easier for autistic children?
- Why do some children with autism struggle with balance?
- Brain zaps tested to calm emotional storms in autism
- Can an AI chatbot help autism caregivers find their way?
- Viruses that eat bacteria: can phages quiet a troubled gut?
- Pregnancy and birth clues: what raises autism risk?